RXRXRecursion Pharmaceuticals, Inc.
$4.36-11% 1Y
$4.36
$2.8452 weeks$6.79
The financials
Recursion Pharmaceuticals, Inc. by the numbers
Recursion Pharmaceuticals, Inc. (RXRX) reported revenue of $7.7M in Q2 2026 (quarter ended Jun 30, 2026), down 60% from the same quarter a year earlier. That came with a gross margin of −50% and net loss of $131M. For the full year FY2025, revenue was $75M (+27% year on year) and net income −$645M. Its largest product in Q2 2026 was License And Service at $7.3M, 95% of the disclosed total, well ahead of Grant at 4.8%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $7.7M | $19M | −60% |
| Gross profit | −$3.8M | −$938K | n/a |
| Operating income | −$135M | −$176M | n/a |
| Net income | −$131M | −$172M | n/a |
| Diluted EPS | −$0.25 | −$0.41 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License And Service | $7.3M | 95% |
| Grant | $367K | 4.8% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $7.7M (+19%)
Grant grew +206% year on yearLicense And Service -62% year on year
Segment Latestquarter on quarteryear on year
- License And Service$7.3M$7.3Mquarter on quarter +16%year on year -62%+16%-62%
- Grant$367.0K$367.0Kquarter on quarter +115%year on year +206%+115%+206%
On our screens:Most shorted stocks